Immuron Ltd (NASDAQ:IMRN)

2.02
Delayed Data
As of Dec 07
 0.00 / 0.00%
Today’s Change
1.69
Today|||52-Week Range
4.40
-19.20%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$16.1M

Company Description

Immuron Ltd. engages in the research and development of oral immunotherapy, which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment is involved in research and development projects performed in Australia, Israel, and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.

Contact Information

Immuron Ltd.
62 Lygon Street
Carlton Victoria (vic) 3053
P:(139) 824-5254
Investor Relations:
613

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Steven LydeamoreChief Executive Officer
Jerry KanellosChief Operating Officer
Phillip Allen HainsChief Financial Officer & Secretary
Dan PeresChief Medical Officer
Reza MoussakhaniDirector-Manufacturing Quality